Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us ![]()
About
AACR Annual meetingAACR Annual meeting
Not Confirmed
Not Confirmed
17-22 April, 2026
Not Confirmed
Not Confirmed
20-22 April, 2026
MAGHREB Pharma ExpoMAGHREB Pharma Expo
Not Confirmed
Not Confirmed
21-23 April, 2026
List your booth number for exhibitions, ask us
CONTACT DETAILS





Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
AACR Annual meetingAACR Annual meeting
Industry Trade Show
Not Confirmed
17-22 April, 2026
Industry Trade Show
Not Confirmed
20-22 April, 2026
MAGHREB Pharma ExpoMAGHREB Pharma Expo
Industry Trade Show
Not Confirmed
21-23 April, 2026
Digital content

30 Mar 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/03/30/3264616/0/en/Transcenta-Therapeutics-Appoints-Dr-Christopher-Hwang-as-Head-of-Global-Partnerships-for-HiCB-Platform.html

24 Feb 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/02/24/3243379/0/en/Transcenta-Therapeutics-to-Present-at-the-36th-Annual-Oppenheimer-Healthcare-Life-Sciences-Conference.html

31 Dec 2025
// INDPHARMAPOST
https://www.indianpharmapost.com/news/transcenta-teams-up-with-eirgenix-to-revolutionise-biologics-manufacturing-18732

28 Dec 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/12/29/3210760/0/en/Transcenta-Therapeutics-Announces-Strategic-Collaboration-and-Non-exclusive-Licensing-Agreement-to-Advance-Integrated-Continuous-Biomanufacturing-and-Expand-Global-Access-to-Afford.html

04 Dec 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/12/05/3200420/0/en/Transcenta-Therapeutics-Presents-Updated-Efficacy-Data-from-the-Phase-I-II-Transtar102-Trial-of-Osemitamab-plus-Nivolumab-and-CAPOX-in-First-Line-G-GEJ-Cancer-at-ESMO-Asia.html

12 Dec 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/transcenta-debuts-promising-anti-tumor-activity-of-novel-liv-1-targeting-adcs-with-site-specific-conjugated-topo-i-inhibitor-payload-in-tnbc-tumor-models-at-2024-sabcs-302330235.html
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE